ClinicalTrials.gg
RecruitingNCT05857670QoLUpdated Feb 1, 2024

Psyco Quality of Life and Procreation BRCA1/2

An observational study in Breast Cancer and Genetic Predisposition, sponsored by Regina Elena Cancer Institute. Recruiting at 2 sites in Italy. Open to female participants aged 25 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Regina Elena Cancer Institute · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
200
Ages
25 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Breast Neoplasms by Regina Elena Cancer Institute — 7 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Regina Elena Cancer Institute.

Planned enrollment
3rd of 11
200 · median 134
Started
2022
with 4 others
Observational
12 of 15
7 open now
Registered
8th of 15
by date

Among the 15 studies in Breast Neoplasms by Regina Elena Cancer Institute, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2022, is one of 12 observational ones, and was the 8th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 15 studies in Breast Neoplasms by Regina Elena Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 25 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Breast Neoplasms by Regina Elena Cancer Institute, or all of them as a file.
02

Study summary

Women with breast and/or ovarian cancer or with a family history carried these pathologies can makeo genetic counseling in order to investigate whether they are carriers of the BRCA1/2 genetic mutation. This mutation exposes them to develop breast cancer from 50 to 80% and from 27 to 65% of developing ovarian cancer. BRCA1/2 mutations are inherited as an autosomal dominant manner and therefore there is a 50% probability of transmitting the mutation to the progeny. For this reason, women who have BRCA 1/2 mutation may be less likely to want children than those who test negative. The decision to have children could worry both for the probability to transfer the genetic mutation or because the parenthood could be compromised by the illness and/or by premature death. In previous studies, the psychological condition of patients with BRCA 1/2 mutations, with or without children, was only partially investigated. For this reason the main goal of the study is to deeply investigate the specific psychological condition, with particular attention to the guilt feelings on the possibility to transfer the genetic mutation to the progeny. In this wai it could be useful to development a therapeutic strategies aimed at the best adaptation of the patients to the new health condition.

03

Conditions studied

  • Breast Cancer
  • Genetic Predisposition
04

Who can participate

Ages eligible
25 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women with BRCA1/2 mutation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with BRCA1/2 mutation affected or not by breast neoplasm
  • Women with BRCA1/2 mutation affected or not by breast neoplasm and with at least a son/daughter
  • Women with at list middle school diploma
  • Women available to do interviews

Exclusion criteria

Exclusion Criteria:

  • Women with other oncological pathology
  • Women with cognitive deficient and/or inability to comply to the requirements of the study
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Interventions

  • BehavioralGenetic predisposition to breast cancer

    Guilt feelings about procreating

06

What researchers measure

Primary outcomes

  1. Evaluation of feeling guilting

    * ISGR-15s * Il PFQ-2 * PHQ-9

    Time frame: 24 monts

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Dec 2023, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2023
First posted
May 12, 2023
StartActual
May 31, 2022
Primary completionActual
Dec 31, 2023
CompletionEst.
Dec 31, 2024
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05857670
Lead sponsor
Regina Elena Cancer Institute
Responsible party
Sponsor
First posted
May 12, 2023
Start date
May 31, 2022
Primary completion
Dec 31, 2023
Completion
Dec 31, 2024 (estimated)
Last update
Feb 1, 2024

Study contacts

Anita Caruso
Contact
anita.caruso@ifo.it
+39 06 52665332

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion